Eterna Therapeutics Inc (ERNA) - Total Liabilities
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has total liabilities worth $2.60 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eterna Therapeutics Inc - Total Liabilities Trend (2006–2024)
This chart illustrates how Eterna Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Eterna Therapeutics Inc (ERNA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Eterna Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Eterna Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Saraswati Griya Lestari Tbk
JK:HOTL
|
Indonesia | Rp78.10 Billion |
|
Rain Enhancement Technologies Holdco, Inc. Class A Common Stock
NASDAQ:RAIN
|
USA | $14.54 Million |
|
ZHONGLIANG HLDG HD-01
F:3ZH
|
Germany | €99.74 Billion |
|
Silver Range Resources Ltd
V:SNG
|
Canada | CA$103.44K |
|
Invert Graphite Limited
AU:IVG
|
Australia | AU$287.84K |
|
J-Long Group Limited
NASDAQ:JL
|
USA | $8.63 Million |
|
Prasidha Aneka Niaga Tbk
JK:PSDN
|
Indonesia | Rp99.71 Billion |
|
HYDROGEN UTOPIA INT.-001
F:D60
|
Germany | €1.06 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Eterna Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ERNA market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eterna Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eterna Therapeutics Inc (2006–2024)
The table below shows the annual total liabilities of Eterna Therapeutics Inc from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.57 Million | -92.39% |
| 2023-12-31 | $46.90 Million | +361.06% |
| 2022-12-31 | $10.17 Million | +68.94% |
| 2021-12-31 | $6.02 Million | +14.75% |
| 2020-12-31 | $5.25 Million | -48.48% |
| 2019-12-31 | $10.19 Million | +28.16% |
| 2018-12-31 | $7.95 Million | -27.98% |
| 2017-12-31 | $11.03 Million | -15.56% |
| 2016-12-31 | $13.07 Million | +0.72% |
| 2015-12-31 | $12.97 Million | +14.38% |
| 2014-12-31 | $11.34 Million | +81.36% |
| 2013-12-31 | $6.25 Million | +31.35% |
| 2012-12-31 | $4.76 Million | -10.10% |
| 2011-12-31 | $5.30 Million | +44.57% |
| 2010-12-31 | $3.66 Million | -24.90% |
| 2009-12-31 | $4.88 Million | +24.59% |
| 2008-12-31 | $3.92 Million | -26.00% |
| 2007-12-31 | $5.29 Million | -33.81% |
| 2006-12-31 | $8.00 Million | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the tr… Read more